Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity

Ballard PYates J.W.TYang ZKim D.-WCHIH-HSIN YANGCantarini MPickup KJordan AHickey MGrist MBox MJohnström PVarnäs KMalmquist JThress K.SJänne P.ACross D.2020-05-262020-05-2620161078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991730676&doi=10.1158%2f1078-0432.CCR-16-0399&partnerID=40&md5=c8f48139a940f312478ff5ac5ea9be5chttps://scholars.lib.ntu.edu.tw/handle/123456789/494971[SDGs]SDG3[SDGs]SDG13Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activityjournal article10.1158/1078-0432.CCR-16-0399274353962-s2.0-84991730676